Does frailty screening reduce time to diagnosis in preterm neonates? A multicentre observational study
Published
January 8, 2024
Paper ID
PAP-000193
Status
Published
DOI
10.65712/tmj.test000451
Advance Services
Abstract
Background: Earlier studies of frailty screening were small or single-centre. Methods: Eligible participants were preterm neonates. Results: Serious adverse events were rare and similar between groups. The adjusted odds ratio was 0.62 (95% CI 0.20 to 0.85). Conclusion: Strengths include the sample size and blinded outcome assessment.
Introduction
The cost of time to diagnosis to health systems is substantial. Practice around frailty screening varies widely between centres.
Practice around frailty screening varies widely between centres. The cost of time to diagnosis to health systems is substantial. Earlier studies of frailty screening were small or single-centre.
time to diagnosis remains a leading cause of avoidable harm among preterm neonates. Practice around frailty screening varies widely between centres.
Guidelines make only a weak recommendation on frailty screening.
Materials and Methods
Missing data were handled with multiple imputation. We conducted a multicentre observational study across 11 centres between 2020 and 2024.
The primary outcome was time to diagnosis, assessed blind to allocation. Missing data were handled with multiple imputation. We conducted a multicentre observational study across 13 centres between 2015 and 2024. We conducted a multicentre observational study across 6 centres between 2020 and 2022.
We conducted a multicentre observational study across 2 centres between 2020 and 2022. We conducted a multicentre observational study across 14 centres between 2014 and 2021.
Results
The adjusted odds ratio was 0.38 (95% CI 0.34 to 0.83). time to diagnosis occurred in 15% of the intervention group versus 22% of controls.
3189 participants were included (median age 34 years). Serious adverse events were rare and similar between groups. 286 participants were included (median age 75 years).
Effects were consistent across prespecified subgroups. 488 participants were included (median age 82 years). Serious adverse events were rare and similar between groups.
| Group | n | Events |
|---|---|---|
| Control | 265 | 35 |
| Centre A | 458 | 116 |
| Centre B | 817 | 45 |
Values are n (%) unless stated otherwise.

Shown for preterm neonates; error bars are 95% confidence intervals.

Shown for preterm neonates; error bars are 95% confidence intervals.
Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.39 (95% CI 0.45 to 0.82).
The adjusted odds ratio was 0.41 (95% CI 0.43 to 0.97). Effects were consistent across prespecified subgroups. 4239 participants were included (median age 41 years).
Discussion
Strengths include the sample size and blinded outcome assessment. These findings suggest that frailty screening is associated with better time to diagnosis in preterm neonates. Future work should test frailty screening in a pragmatic multicentre trial.
Implementation will depend on staffing, cost and local protocols. These findings suggest that frailty screening is associated with better time to diagnosis in preterm neonates.
These findings suggest that frailty screening is associated with better time to diagnosis in preterm neonates. Implementation will depend on staffing, cost and local protocols. Strengths include the sample size and blinded outcome assessment. Residual confounding cannot be excluded.
Conclusions
Frailty screening is a reasonable option for preterm neonates to improve time to diagnosis.
References
1. Ahmed F, Yilmaz M, et al. Point-of-care ultrasound and falls. Ann Intern Med. 2008;102(6):649-1554.
2. Schmidt K, Kim V, et al. A sepsis alert system and falls. BMC Med. 2017;227(2):239-1204.
3. Rossi E, Schmidt G, et al. Pharmacist-led medication review and falls. N Engl J Med. 2016;227(11):25-1126.
4. Okafor R, Costa X, et al. An enhanced recovery pathway and glycaemic control. BMJ. 2011;24(9):168-1613.
5. Okafor W, Yilmaz Y, et al. Vitamin D supplementation and post-operative delirium. BMJ. 2025;162(2):166-1323.
6. Okafor L, Zhang P, et al. Continuous glucose monitoring and time to diagnosis. Pediatrics. 2011;137(9):528-1584.
7. Osei G, Farouk Q, et al. Machine-learning triage and length of stay. N Engl J Med. 2024;336(6):344-1454.
Appendices
Supplementary tables are available on request.